JP2019532092A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532092A5
JP2019532092A5 JP2019522803A JP2019522803A JP2019532092A5 JP 2019532092 A5 JP2019532092 A5 JP 2019532092A5 JP 2019522803 A JP2019522803 A JP 2019522803A JP 2019522803 A JP2019522803 A JP 2019522803A JP 2019532092 A5 JP2019532092 A5 JP 2019532092A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
heteroatoms selected
substituted
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019522803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532092A (ja
JP7145850B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/058645 external-priority patent/WO2018081488A1/en
Publication of JP2019532092A publication Critical patent/JP2019532092A/ja
Publication of JP2019532092A5 publication Critical patent/JP2019532092A5/ja
Application granted granted Critical
Publication of JP7145850B2 publication Critical patent/JP7145850B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019522803A 2016-10-28 2017-10-27 Il-12、il-23および/またはifnアルファ応答の調節剤として有用なヘテロ二環化合物 Active JP7145850B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662414158P 2016-10-28 2016-10-28
US62/414,158 2016-10-28
PCT/US2017/058645 WO2018081488A1 (en) 2016-10-28 2017-10-27 Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Publications (3)

Publication Number Publication Date
JP2019532092A JP2019532092A (ja) 2019-11-07
JP2019532092A5 true JP2019532092A5 (enExample) 2020-11-12
JP7145850B2 JP7145850B2 (ja) 2022-10-03

Family

ID=60263169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522803A Active JP7145850B2 (ja) 2016-10-28 2017-10-27 Il-12、il-23および/またはifnアルファ応答の調節剤として有用なヘテロ二環化合物

Country Status (8)

Country Link
US (1) US10781215B2 (enExample)
EP (1) EP3532473B1 (enExample)
JP (1) JP7145850B2 (enExample)
KR (1) KR102477063B1 (enExample)
CN (1) CN110114357B (enExample)
ES (1) ES2895107T3 (enExample)
MA (1) MA46620A (enExample)
WO (1) WO2018081488A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
JP6557436B1 (ja) 2018-03-12 2019-08-07 アッヴィ・インコーポレイテッド チロシンキナーゼ2媒介性シグナル伝達の阻害剤
TWI800696B (zh) * 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
EP3946350A4 (en) * 2019-03-26 2022-09-07 Ventyx Biosciences, Inc. TYK2 PSEUDOKINASE LIGANDS
AU2019443366A1 (en) 2019-04-30 2021-12-02 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
CA3160637A1 (en) 2019-11-08 2021-05-14 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
US11697648B2 (en) * 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
CN116283993B (zh) * 2021-12-20 2024-05-03 艾立康药业股份有限公司 一种嘧啶类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
JP5298128B2 (ja) 2007-08-08 2013-09-25 グラクソスミスクライン エルエルシー 癌の治療用のIGF−1R阻害剤としての2−[(2−{フェニルアミノ}−1H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]ベンズアミド誘導体
EA018282B1 (ru) * 2008-04-07 2013-06-28 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
CA2890935A1 (en) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
USRE47690E1 (en) 2014-05-14 2019-11-05 The Regents Of The University Of Colorado, A Body Corporate Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2019532092A5 (enExample)
JP2019530699A5 (enExample)
JP2015514806A5 (enExample)
CY1124728T1 (el) Παραγωγα βενζοξαβορολης για τη θεραπεια βακτηριακων λοιμωξεων
JP2015514808A5 (enExample)
JP2016536363A5 (enExample)
JP2016534134A5 (enExample)
JP2018529739A5 (enExample)
JP2016532715A5 (enExample)
JP2019081762A5 (enExample)
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
JP2016501185A5 (enExample)
JP2015535277A5 (enExample)
JP2016506369A5 (enExample)
JP2016518328A5 (enExample)
JP2012140432A5 (enExample)
JP2017535614A5 (enExample)
RU2014140735A (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2016503799A5 (enExample)
JP2008505194A5 (enExample)
JP2016521710A5 (enExample)
JP2020502268A5 (enExample)
JP2016040262A5 (enExample)
RU2020131276A (ru) Терапевтические соединения и композиции
JP2016531868A5 (enExample)